hepatocellularcarcinoma
Conditions
Interventions
intra-arterial injection of miriplatin suspension from the hepatic artery
Sponsors
tokushima university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with hepatocellular carcinoma clinical such as angiography, CT, and MRI or histologically Patients with off-label liver resection, PEI and RFA Patient had never received chemotherapy TAE. PEI or liver resection, RFA is acceptable. However, PEI , RFA and post-stump recurrence after hepatectomy I will improper local recurrence. Child Pugh A or B Patients must be expected to survive more than two months at least organ function below, the patient sufficient bone marrow, renal, cardiovascular is maintained. Liver has sufficient compensatory physiologically function. WBC or more 3,000 per micro litter PLT or more 50000/micro litter Hb or more 9.5g/micro litter AST or less 200 U/L ALT or less 200 U/L Serum bilirubin or less 3mg/dL Serum creatinine or less facility upper limit of normal Patients to confirm that it also has a structure of appropriate hepatic artery for catheter insertion selective the general state, Performance Status is of 0, 1, and 2 patients The elapsed more than 4 weeks at least from before treatment, liver resection, the RFA or PEI, patients without the influence of prior treatment
Exclusion criteria
Exclusion criteria: (1) Patients with a history of hypersensitivity to contrast agent or drug, including Iodine (2) Patients with (thyroid disease particularly severe, severe cardiac disease) complications (3) serious Patients with double cancer activity (4) Patients with intrahepatic shunt (5) Patients with distant metastases (6) Patients with intention of pregnancy, pregnant women, and lactating women (7) Patients with investigator or investigator was found to be inappropriate as a target
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| responce rate | — |
Secondary
| Measure | Time frame |
|---|---|
| The extent and frequency of occurrence of adverse events and survival rate | — |
Countries
Japan
Contacts
Public Contacttanaka hironori
university of tokushima graduate school department of gastroenterology and oncology, instituteof health bioscience
Outcome results
None listed